On this page:OverviewFunded papers
ScholarIQanswers from OpenAlex

Daiichi Sankyo Company

FunderResearch funding and supported work

Daiichi Sankyo Company is a funder indexed in ScholarIQ from OpenAlex.

What is known about Daiichi Sankyo Company?

ScholarIQrecord summary

Japanese pharmaceutical company

How many works does Daiichi Sankyo Company have?

ScholarIQindexed works

Daiichi Sankyo Company has 1,224 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

What is the OpenAlex record for Daiichi Sankyo Company?

ScholarIQopenalex

The OpenAlex for Daiichi Sankyo Company is on the source record.

What is the ROR of Daiichi Sankyo Company?

ScholarIQror

The ROR for Daiichi Sankyo Company is on the source record.

What are the most-cited papers on Daiichi Sankyo Company?

ScholarIQmost cited works
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Michael Offin, Joseph M. Chan, Megan Tenet, Hira Rizvi, Ronglai Shen, Gregory J. Riely, Natasha Rekhtman, Yahya Daneshbod, Àlvaro Quintanal-Villalonga, Alexander Penson, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Dana Pe’er, Mark G. Kris, Charles M. Rudin, Helena A. Yu
Journal of Thoracic Oncology. 2019458 CitationsOPEN ACCESS
470M+ articles · 14-day free trial